Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population
- 28 August 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 240 (2), 261-267
- https://doi.org/10.1016/j.canlet.2005.09.019
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Time trends in cancer mortality in China: 1987–1999International Journal of Cancer, 2003
- The p53 and Mdm2 families in cancerCurrent Opinion in Genetics & Development, 2002
- Breast cancer: hormones and other risk factorsMaturitas, 2001
- The MDM2 RING-finger domain is required to promote p53 nuclear exportNature, 2000
- Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53Proceedings of the National Academy of Sciences of the United States of America, 1999
- Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev proteinThe EMBO Journal, 1998
- Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 GeneMolecular Medicine, 1997
- Breast cancer risk and environmental exposures.Environmental Health Perspectives, 1997
- Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.Journal of Bone and Joint Surgery, 1997
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997